Runs clinical trials testing drug compounds for NASH, a liver disease that currently has no approved treatment.
At a glance
- Depends onMidstream position: 3 outgoing, 3 incoming connections
- ScaleRevenue is in the bottom 5% globally
Runs clinical trials testing drug compounds for NASH, a liver disease that currently has no approved treatment.
Terns Pharmaceuticals runs clinical trials testing small molecule drugs against NASH, a liver disease with no FDA-approved treatment, where the only way to prove a drug works is to take a biopsy of the patient's liver before treatment and again years later to see whether the scarring has actually reversed. Because that biological process cannot be rushed, every dollar the company spends burns against a fixed multi-year clock before any efficacy result is possible. The hepatology centers running these biopsies build up years of protocol-specific experience with Terns' particular procedures and patient cohorts, which a competitor could not simply replicate — matching it would mean restarting that entire enrollment and follow-up clock from scratch. The whole structure depends on the FDA continuing to require liver biopsy as its accepted proof standard, because if regulators shift to a non-invasive blood marker instead, every enrolled patient, every site relationship, and every data package Terns has accumulated would need to be rebuilt against a different evidentiary baseline.
How does this company make money?
The company does not yet earn revenue. It runs on equity financing — money raised from investors — and could receive cash through licensing deals if a pharmaceutical company pays to access or co-develop one of its compounds. If a drug is eventually approved, revenue would come from prescription sales routed through specialty pharmacy channels that also handle the required liver monitoring for patients on the drug.
What makes this company hard to replace?
Clinical investigators at hepatology centers build deep familiarity with this company's specific trial protocols and cannot simply apply that knowledge to a different compound mid-study. The proprietary clinical data packages built inside each trial are tied to this company's drug and regulatory filings and cannot be transferred to another program. Patients already enrolled in a biopsy-confirmed trial cannot be immediately re-recruited into a competing study — they are committed to this protocol's multi-year follow-up window.
What limits this company?
The liver takes years to show measurable improvement in scarring. No amount of money or extra staff can make that biological process happen faster. Every dollar the company spends on salaries, trial sites, and lab work burns against that fixed timeline, and no efficacy result is possible until the biology delivers one.
What does this company depend on?
The company cannot operate without FDA Investigational New Drug approvals for each clinical candidate. It also depends on specialized hepatology clinical sites that can perform liver biopsies, contract manufacturing organizations that produce its small molecule compounds under pharmaceutical-grade conditions, contract research organizations experienced in NASH trial design, and patients who have already received a liver biopsy confirming their NASH diagnosis.
Who depends on this company?
Hepatology specialists at academic medical centers depend on this company's trials because their NASH patients currently have no treatment options beyond diet and exercise. Contract research organizations focused on liver disease trials depend on active NASH development programs for their own revenue. Specialty pharmacy networks that would distribute approved NASH drugs — and handle the liver function monitoring those drugs require — are also waiting on successful development.
How does this company scale?
Once a drug formulation is established, producing more of the compound through contract manufacturing organizations is relatively straightforward and cost-efficient. What cannot be scaled up quickly is the clinical trial itself — adding more hepatology centers still requires site setup, biopsy-confirmed patient enrollment, and years of follow-up, and the FDA's phase requirements set a floor that cannot be skipped.
What external forces can significantly affect this company?
Medicare reimbursement policies will shape whether an approved NASH drug is financially accessible to patients, which affects how commercially valuable the company's work actually becomes. FDA guidance on acceptable NASH endpoints is the single most consequential external force — any shift away from liver biopsy as the required proof standard would restructure every active program. The rising prevalence of metabolic syndrome and diabetes is expanding the potential patient population, but it is also drawing large, well-funded diabetes drug manufacturers into the NASH space as competitors.
Where is this company structurally vulnerable?
If the FDA changes its rules and decides that a blood marker or scan — rather than a liver biopsy — is enough to prove a NASH drug works, every active trial this company is running would need to be redesigned from the beginning. The years of biopsy data already collected, and the specialized expertise built up at hepatology sites, would no longer satisfy the new standard, erasing the head start the company currently holds.
Sign in to view price data.
Sign inStructural observations derived from financial data, industry benchmarks, and supply chain position.
Companies that share the same coordination system — how they create, deliver, or capture value.
Companies that share active interpretations — structural patterns currently present in both stocks.
CompanyGraph